Objective To implement a standardized approach to characterize neurologic outcomes among 12-month survivors in the Therapeutic Hypothermia after Pediatric Cardiac Arrest (THAPCA) trials.
Children who remain comatose after cardiac arrest (CA) resuscitation experience high rates of long-term functional impairment. Recent independent parallel randomized clinical trials compared 2 targeted temperature management interventions in pediatric CA survivors, one for patients with in-hospital CA and one for patients with out-of-hospital CA, in pediatric intensive care units at 37 hospitals in North America and Great Britain (Therapeutic Hypothermia After Pediatric Cardiac Arrest [THAPCA]-IH, NCT NCT00880087; THAPCA-OH, NCT00878644). The primary neurologic inclusion criterion was a Glasgow Coma Scale motor response below 5 within 6 hours after return of circulation; a score of 5 represents localizing pain or, if under age 2 years, withdrawing to touch. The primary efficacy outcome was 12-month survival with favorable neurobehavioral outcome, defined as composite score 70 or higher on the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) (scaled from 20 to 160 with higher scores indicating better function). Only individuals with pre-CA VABS-II scores at least 70 were eligible for the primary outcomes. In both trials, the primary outcome did not differ between treatment groups.
A total of 179 surviving children, all eligible for the primary outcomes, aged 1-18 years, underwent neurologic examinations at 12 months to characterize their neurologic impairments and delineate the neurologic correlates of adaptive functional deficits measured with VABS-II. We developed a standardized semiquantitative format, the Pediatric Resuscitation after Cardiac Arrest (PRCA) form, similar to the Pediatric Stroke Outcome Measure (PSOM), 1 to describe findings. The major adaptations in PRCA were expansion of the score range and addition of a domain to capture nonlateralizing or brainstem function deficits.
Methods
THAPCA study design Details of study design, outcome selection, protocols, inclusion and exclusion criteria, and outcomes for the THAPCA trials have been published. 2, 3 The trials enrolled children older than 48 hours and younger than 18 years who sustained CA, required chest compressions for at least 2 minutes, and remained comatose and dependent on mechanical ventilation after return of circulation. Major exclusion criteria were traumatic brain injury; scores of 5 or 6 on the Glasgow Coma Scale motor response subscale (scored 1-6, low scores are worse; scores of 5-6 indicate age-appropriate lateralized response to pain); inability to randomize within 6 hours; life expectancy less than 12 months; and lack of commitment to aggressive care. THAPCA-OH included cases of out-of-hospital CA (with few preexisting medical conditions); THAPCA-IH included patients whose CA began within a hospital. In both trials, the primary outcome was survival with favorable neurobehavioral outcome at 12-month follow-up, defined as VABS-II score 70 or higher.
VABS-II provides age-corrected standard scores in 4 domains (communication, daily living, socialization, motor skills) and an overall adaptive behavior composite score (mean score 100, SD 15). VABS-II includes a parent/caregiver rating form and a survey interview (using caregiver as informant) that yield comparable scores. 4 Pre-CA function was evaluated using the VABS-II parentcaregiver questionnaire, completed on-site within 24 hours of randomization. The 3-and 12-month outcome VABS-II data were collected centrally (Kennedy Krieger Institute, Baltimore, MD) via telephone by a trained interviewer unaware of treatment assignment. As prespecified, enrolled children with pre-CA VABS-II scores below 70 were excluded from the primary efficacy analyses, but remained in the studies. Patients with no baseline VABS-II data available were eligible for primary analyses if their baseline Pediatric Overall Performance Category (POPC) and Pediatric Cerebral Performance Category (PCPC) scores were in normal or mild disability categories (1 or 2). Scores range from 1 to 6 and lower scores represent less disability; PCPC measures neurologic functioning whereas POPC measures overall health. 5 These clinician-rated scales have been used to report outcomes following pediatric CA. [5] [6] [7] [8] [9] PCPC scoring guidelines for THAPCA 10 and details of VABS-II 3-and 12-month scores for both trials have been reported. [10] [11] [12] Neurologic assessments The study protocols did not include early neurologic examinations, apart from GCS motor response assessment (by a pediatric critical care physician site investigator); nor was any neurodiagnostic testing specified. Clinical seizure recognition was documented daily during the initial 5-day intervention period.
Neurologic examinations were performed at 12-month follow-up (except at UK sites that joined THAPCA-IH late in its course). This report includes data on 12-month survivors who were eligible for the primary outcome (i.e., with broadly normal baseline function), for whom subsequent neurologic deficits were most likely attributable to CA.
Outcomes in survivors who were ineligible for the primary outcome will be reported separately. Of 270 eligible THAPCA-OH patients, 87 survived for 1 year; 75/87 (86%) underwent neurologic examination. Of 257 eligible THAPCA-IH patients, 135 survived for 1 year; 104/135 (77%) underwent 12-month neurologic examination. Neurologic evaluations were scheduled after VABS-II assessments: cognitive testing (Mullen up to age 5 years 9 months, 13 and Wechsler Abbreviated Scale of Intelligence [WASI] over age 6 years 14 ) was scheduled on the same day. Composite cognitive scores have been reported. 2, 3, 11, 12 Each site investigator identified at least one pediatric neurologist who agreed to participate. Orientation meetings were held at the 2011 and 2012 Child Neurology Society meetings. Two pediatric neurologists (R.I., F.S.S.) were available for consultation regarding scoring. Neurologists were instructed to perform a conventional, detailed age-appropriate neurologic examination, and to record and score each element of the examination using a novel method we developed for this study, the Pediatric Resuscitation after Cardiac Arrest (PRCA) form (appendix e-1, links.lww.com/WNL/A571 and appendix e-2, links.lww.com/ WNL/A572). This was developed as a modification of the PSOM instrument. 1 Versions were developed for children under age 3 years, and for older children, reflecting age-related items for assessing language and cognition. As with the PSOM, they were also asked to complete global assessments and assign scores (from 0, normal, to 3, severe impairment) in 6 domains. Sensorimotor function was scored independently for each side of the body (so that scores ranged from 0 to 6); the 5 other scored domains included other nonlateralizing sensorimotor function (encompassing cranial nerve deficits, movement/tone disorder, global delays), language production, language comprehension, cognition, and behavior. Total PRCA scores ranged from 0 to 21, with 0 indicating no deficits and 21 indicating maximal deficits.
PRCA forms were submitted to the University of Utah Data Coordinating Center (DCC), and subsequently reviewed for legibility, completeness, and scoring consistency relative to findings described in neurologic examination elements (by R. I. and F.S.S.). When inconsistencies or lack of clarity was apparent, the site neurologist was contacted, revisions were made, and final adjudications were submitted to the DCC (by R.I., except examinations performed by R.I. were reviewed by F.S.S.).
Standard protocol approvals, registrations, and patient consents
Institutional review boards of all sites approved the protocol and informed consent documents.
Data analysis
Patient characteristics were compared between studies using the Wilcoxon rank-sum test, Fisher exact test, or the CochranArmitage test for trend. Pearson correlation coefficients were calculated to assess associations between PRCA and other assessments. To quantify association of factors with PRCA scores, standard linear regression models were evaluated first in univariate models; candidate predictors (p < 0.10) were then included in multivariable models. All analyses were completed using SAS software version 9.4 (Cary, NC).
Data availability
Anonymized data will be shared by request from any qualified investigator. Table 1 describes CA survivors who were eligible for the THAPCA trial primary outcomes and underwent neurologic examinations at 1 year follow-up, 104 from THAPCA-IH and 75 from THAPCA-OH. There were many differences between these groups. In-hospital cases were younger (68% vs 32% <3 years old), had slightly lower baseline VABS-II scores (96 vs 100), included more with cardiac etiology of CA (65% vs 20%), received more epinephrine doses (4.5 vs 2.9), and differed from the out-of-hospital group with respect to durations of chest compression. Treatment group assignment did not differ. Seizure diagnosis during the intervention period was more common in the out-of-hospital group (41% vs 17%). PCPC score at hospital discharge differed significantly, with 69% classified as normal or mild disability in the in-hospital group, compared with 35% of out-of-hospital survivors. Similarly, 12-month VABS-II composite scores were higher in the in-hospital group (mean 84 vs 69 in the out-of-hospital group).
Results
We also evaluated these characteristics in 41 survivors, eligible for the primary outcomes, who did not undergo neurologic examination, and compared them with the 181 cases who did (2 with partial PRCA data were excluded from subsequent analyses). The 2 cohorts did not differ in any measure (data not shown). Table 2 provides detailed information about PRCA scores in all children evaluated. The mean PRCA global assessment score of 7.7 (out of a maximum of 21) reflected some degree of impairment in multiple domains in most children. Sensorimotor deficits were variable and generally global or nonlocalizing. Major findings discerned included consistently lower composite and domain scores (i.e., fewer abnormalities) in in-hospital than out-of-hospital cases, no significant differences between treatment arms in the out-of-hospital study group, and one very minor difference in cognitive deficit scores (0.6 vs 0.9, favoring therapeutic normothermia) in the in-hospital cohort.
The distribution of PRCA scores was stratified into 5 groups, shown in figure 1 , and summarized as follows: no or minimal impairment, PRCA 0-3 in 81/179 (45%); mild impairment, PRCA 4-7 in 24/179 (13%); moderate impairment, PRCA 8-11 in 15/179 (8%); severe impairment, PRCA 12-16 in Data from 50 children with PRCA scores of 0 (i.e., classified as neurologically normal) were examined separately. In this distinct subpopulation (age 1-18 years; mean ± SD, 6.3 ± 6 years; 34/50 from in-hospital study), pre-CA VABS-2 scores were average (100 ± 17), and declined minimally (95 ± 13); cognitive composite scores were in a similar range (94 ± 20). Of note, estimated cardiopulmonary resuscitation duration was 30-40 minutes in 6 cases, and over 40 minutes in 10 cases. Figure 2 illustrates the relationship between early clinical assessments (PCPC scores, from 1 to 5, at hospital discharge) and subsequent 12-month neurologic outcome scores (0-21). Of note, the mean duration of hospitalization after CA until discharge, when this score was assigned, was 46 days (53 days for the in-hospital group and 37 days for the out-of-hospital group). Although hospital discharge PCPC strongly predicted 12-month PRCA scores (r = 0.74, p < 0.0001 Pearson correlation coefficient), individual patients had diverging trajectories. One young infant with a PCPC score of 5 at hospital discharge improved markedly and had a normal 12-month neurologic examination (PRCA = 0). Some individuals classified as normal or mildly impaired at hospital discharge had significant impairments at 12-month assessments. However, details of posthospital discharge medical complications that likely contributed to subsequent neurologic declines were not collected in the study protocols. Nor was any information about neurodiagnostic testing or rehabilitation services collected. Table 3 describes the predictors of outcome measured by the 12-month PRCA score. In univariate analyses, CA characteristics that were associated with an increased risk of poor outcome included site (out-of-hospital worse than in-hospital), primary etiology (respiratory worse than cardiac), and longer duration of chest compressions. Post-CA variables that influenced outcome included seizure detection during the 5-day intervention period, greater length of hospital stay, and hospital discharge PCPC. Treatment group, age, and sex of the child and first lactate level did not predict 12-month outcome. However, in a model that included only CA characteristics (model 1) these variables, together, were very weak predictors of outcome (R 2 = 0.21). A model that incorporated post-CA variables more robustly predicted PRCA scores (R 2 = 0.63). Yet, as illustrated in figure 2, e128 Neurology | Volume 91, Number 2 | July 10, 2018 Neurology.org/N although neurologic status at hospital discharge was strongly correlated with 12-month neurologic examination scores, unidentified factors also contributed substantially to individual variation in 12-month PRCA scores.
Discussion
We evaluated a unique cohort of prospectively evaluated children, who survived for 1 year after cardiac arrest with initial postresuscitation coma. These children, ranging in age from 1 to 18 years, had a broad range of neurologic outcomes. The spectrum of outcomes was approximately evenly distributed among 3 broad categories of normal or near normal, mild to moderate impairment, and severe impairment. Those children with severe impairment typically had mixed severe motor, cognitive, and adaptive functional deficits.
Our study demonstrated that neurologic assessment using the PRCA is a powerful method for depicting neurologic outcomes after acute encephalopathy caused by cardiac arrest Neurology.org/N Neurology | Volume 91, Number 2 | July 10, 2018 e129 in children. It provides both a global semiquantitative rating of neurologic impairment as well as more specific characterization of localizing deficits and domain-specific impairment. The strong correlation with previously well-established measures of functional and cognitive outcomes (VABS-II, Mullen, WASI) provides support for the validity of the PRCA in children with CA from a range of ages, widely varying underlying diseases, and wide spectrum of outcomes in these trials. The PRCA represents a novel approach to standardizing assessment of neurologic outcome following an acute diffuse brain injury across a broad pediatric age range. It builds upon the strengths of the widely used PSOM for assessing long-term stroke outcomes in children. [15] [16] [17] Both are based on detailed standard neurologic examinations, and standardized ratings in multiple key functional domains using a simple Likert scale for each domain, relative to age-specific expectations. By expanding total scores from a maximum of 10 in PSOM up to 21, the PRCA had a greater capacity to capture variability in neurologic status over the full range of outcomes seen in this population.
An integral element of this study was the central review procedure. Orientation and central review of all PRCA data provided an important means to standardize the assessment and to clarify questions or discrepancies in administration and interpretation by site neurologists. Challenges with interpretation or scoring that were reported centered on the difficulties of scoring the cognitive subscale in children with motor impairment, and the subjective nature of differentiating degrees of severity in the subscale scores. These problems are inherent to any rating scale of this nature. Despite these challenges, our finding of robust correlations of the PRCA scores compared to other well-established functional endpoint assessments suggest that the PRCA, when administered with centralized, consistent oversight, is a valid method to measure neurologic outcome over a broad range of variation after diffuse brain injury in children.
Comparison of PRCA scores between in-hospital CA and outof-hospital CA groups demonstrated substantial differences, congruent with findings of our prior retrospective study. 18 There were major differences in underlying disease characteristics of these 2 populations, cardiac etiologies more common in in-hospital arrest and respiratory etiologies more common in out-of-hospital arrest, and neurologic outcomes were worse in out-of-hospital than in in-hospital CA survivors. In fact, awareness of these inherent differences justified the conduct of independent trials of therapeutic hypothermia for in-hospital and out-of-hospital pediatric CA.
Analysis of outcome predictors in surviving children who underwent 12-month neurologic examinations was challenging. As in the parent THAPCA trials, hypothermia did not confer any benefit, compared with normothermia. Although several contributing factors were identified in univariate analyses, in multivariate models postarrest factors, including seizure recognition in the first 5 days postresuscitation and poor neurologic status at hospital discharge, were more powerful than prearrest or intra-arrest factors.
In particular from a neurologic perspective, our data had significant limitations. No element of the neurologic examination apart from the Glasgow Motor Scale was consistently documented prior to enrollment. Although EEGs and neuroimaging were frequently performed in patients enrolled in these trials, no neurodiagnostic or biomarker testing was included in the THAPCA protocols, and no information about results of these tests was collected centrally. The data element that described presence or absence of seizures during the intervention period was broadly defined to encompass clinical or electrographic seizures, as recognized by the local clinical teams. The distribution of neurologic outcomes at 12 months in survivors must also be interpreted with caution, as an early clinical assessment of poor neurologic outcome led to redirection of goals of care for some children in each trial.
Our observations have important implications for clinical care as well as for the design of future studies of outcome in children surviving CA. Our findings suggest that attempts to prognosticate during the acute hospital phase should be undertaken with caution, and some children make significant improvements during the first year after their initial insult.
In future clinical trials that enroll children at substantial risk for neurologic impairment, standardized neurologic examinations have the potential to yield robust, clinically meaningful outcome measures.
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